B7-33: The Non-Oncogenic Alternative for Relaxin-2 Receptor Research

The pharmacological potential of native human relaxin-2 (RLN2) in mitigating fibrotic disorders is well-documented, yet its laboratory utility is hindered by its complex two-chain structure and association with oncogenic pathways. Native RLN2 binds to the Relaxin Family Peptide Receptor 1 (RXFP1), initiating pleiotropic tissue-remodelling cascades via Gs-mediated adenylyl cyclase activation but also upregulating pathways linked to tumour metastasis. To address this, B7-33 was synthesised as a single-chain, 24-amino-acid peptide engineered from the receptor-binding domain of the RLN2 B-chain. This review characterises B7-33 as a highly selective, biased agonist of RXFP1. In-vitro investigations demonstrate that B7-33 preferentially activates the extracellular signal-regulated kinase 1/2 (pERK1/2) pathway and stimulates cyclic adenosine monophosphate (cAMP) accumulation in fibroblasts, suppressing myofibroblast differentiation and collagen deposition without recruiting the intracellular machinery responsible for tumour cell migration. B7-33 represents a robust, non-oncogenic alternative for investigating relaxin-mediated anti-fibrotic pathways in laboratory settings.

Structural Characterisation of B7-33

Relaxin-2 is a naturally occurring peptide hormone consisting of an A-chain and a B-chain linked by three disulfide bonds. This complex architecture presents significant challenges for chemical synthesis and purification. Beyond synthetic obstacles, in pathological states, the activation of RXFP1 by native relaxin-2 has been shown to accelerate tumour progression and facilitate metastasis. This oncogenic potential complicates the study of relaxin-2 receptor activity in heterogeneous cell cultures.

Figure 1: An abstract, unlabeled 2D scientific node-and-network biological representation on a dark screen, showcasing molecular pathways with cyan and amber lighting.

B7-33 was designed to overcome these limitations. By isolating the active binding region of the relaxin B-chain, researchers identified a truncated sequence corresponding to residues 10 to 33. This single-chain peptide lacks the complex inter- and intra-chain disulfide-bonded A-chain, resolving the synthetic folding bottlenecks associated with native multi-chain peptide synthesis. Despite its simplified structure, B7-33 retains a high affinity for the RXFP1 receptor. The primary sequence is modified to preserve alpha-helical secondary structure in aqueous environments, which is critical for docking into the leucine-rich repeat (LRR) domain of the RXFP1 extracellular ectodomain. Unlike the parent molecule, B7-33 adopts a stable conformation that readily interacts with the extracellular domain of RXFP1, initiating downstream signalling events with high specificity.

Molecular Pharmacology and Biased Agonism

The molecular pharmacology of B7-33 is defined by its biased agonism at the RXFP1 receptor. When native relaxin-2 binds to RXFP1, it triggers a robust accumulation of cAMP via Gs-protein coupling and adenylyl cyclase activation, while simultaneously recruiting the G-protein beta-gamma subunits to activate the phosphatidylinositol 3-kinase (PI3K)/Akt pathway and upregulating matrix metalloproteinase-9 (MMP-9) expression. This multi-pathway activation is responsible for both the beneficial anti-fibrotic effects and the undesirable pro-oncogenic properties.

In contrast, B7-33 exhibits a highly distinct signalling bias at the RXFP1 receptor. In-vitro assays demonstrate that B7-33 selectively stimulates cAMP accumulation and pERK1/2 phosphorylation in primary fibroblasts, while completely failing to recruit the beta-arrestin-2 or PI3K/Akt pathways. This selective activation profile makes B7-33 an invaluable tool for dissecting the specific intracellular pathways that mediate tissue remodelling without triggering proliferative or migratory cascades. By selectively activating the pERK1/2 pathway, B7-33 promotes the transcription of genes associated with extracellular matrix degradation while avoiding the activation of survival pathways that prevent apoptosis in aberrant cell lines.

Anti-Fibrotic Efficacy in Laboratory Models

In-vitro research using primary cell cultures has confirmed the potent anti-fibrotic properties of B7-33. When applied to cardiac, renal, or pulmonary fibroblasts, B7-33 effectively counteracts the pro-fibrotic effects of transforming growth factor-beta 1 (TGF-beta 1). TGF-beta 1 drives fibrosis, inducing the differentiation of quiescent fibroblasts into active myofibroblasts, characterised by alpha-smooth muscle actin (alpha-SMA) expression and excessive extracellular matrix secretion. B7-33 application significantly reduces alpha-SMA expression and downregulates the transcription of collagen type I and type III genes. Furthermore, B7-33 enhances the expression of matrix metalloproteinase-2 (MMP-2), facilitating the degradation of pre-existing collagen fibres. This dual action—suppressing new collagen synthesis while promoting the clearance of existing deposits—highlights the efficacy of B7-33 as a research tool for studying tissue regeneration. For laboratories focusing on cellular energetics and tissue repair, combining these pathways with other metabolic regulators can yield comprehensive insights, similar to how ss-31 elamipretide targets mitochondrial dysfunction to preserve cellular integrity during oxidative stress.

Mitigating the Oncogenic Risk in Research

One of the most significant advantages of B7-33 over native relaxin-2 is its lack of oncogenic activity. In oncology research, the RXFP1 receptor is frequently studied due to its upregulation in various cancers, including prostate, breast, and ovarian malignancies. In these contexts, native relaxin-2 acts as a growth factor, promoting epithelial-mesenchymal transition (EMT), angiogenesis, and cell survival. This makes the use of native relaxin-2 highly problematic in co-culture models where researchers aim to study the interaction between fibrotic stromal cells and epithelial cells.

B7-33 resolves this issue by failing to induce the migration or proliferation of cancer cells expressing RXFP1. In-vitro migration assays have demonstrated that while native relaxin-2 significantly increases the invasiveness of prostate cancer cell lines, B7-33 has no such effect. This safety profile allows for the precise investigation of RXFP1-mediated anti-fibrotic mechanisms in complex, multi-lineage cellular environments without the risk of inducing uncontrolled cellular proliferation.

Reconstitution, Stability, and Laboratory Storage

To ensure the reproducibility of in-vitro experiments, proper handling and reconstitution of B7-33 are paramount. The peptide is typically supplied as a lyophilised powder and should be stored at -20 degrees Celsius for long-term stability. For experimental applications, the peptide must be reconstituted using a suitable sterile solvent, such as a bacteriostatic reconstitution solution or standard sterile water-equivalent laboratory solvents. Due to its single-chain structure, B7-33 is less prone to aggregation and enzymatic degradation than native relaxin-2, offering superior stability in cell culture media. However, researchers should avoid repeated freeze-thaw cycles by aliquotting the reconstituted solution into single-use volumes. Employing high-quality peptide research reagents ensures that experimental outcomes remain consistent.

Frequently Asked Questions

How does B7-33 structurally differ from native human relaxin-2?

Native human relaxin-2 is a complex, two-chain peptide consisting of an A-chain and a B-chain held together by three disulfide bonds. In contrast, B7-33 is a simplified, single-chain peptide containing only 24 amino acids derived from the B-chain of relaxin-2. It lacks the A-chain and the associated disulfide bonds, reducing synthesis complexity while maintaining high binding affinity for the RXFP1 receptor.

What is the molecular mechanism behind B7-33's biased agonism at the RXFP1 receptor?

B7-33 acts as a biased agonist by selectively activating specific downstream signalling pathways of the RXFP1 receptor. While native relaxin-2 activates multiple pathways including cAMP, pERK1/2, and the pro-oncogenic PI3K/Akt pathway, B7-33 preferentially triggers cAMP accumulation and ERK1/2 phosphorylation in fibroblasts. It does not activate the PI3K/Akt pathway or upregulate MMP-9 in the same manner as native relaxin-2.

Why is B7-33 preferred over native relaxin-2 in oncology-adjacent research models?

In co-culture and tissue models that involve both fibrotic stromal cells and epithelial cells, native relaxin-2 can promote epithelial-mesenchymal transition, cell migration, and metastasis due to its activation of oncogenic pathways. B7-33 is preferred because it does not induce these proliferative or invasive cellular behaviours, allowing researchers to study the anti-fibrotic effects of RXFP1 activation without the confounding variable of promoting tumour-like cellular phenotypes.

Scientific References

• Hossain, M. A., et al. (2016). 'A single-chain peptide agonist of the relaxin receptor RXFP1.' Journal of Biological Chemistry, 291(21), 11108-11118. View published research
• Bathgate, R. A., et al. (2013). 'Relaxin family peptides and their receptors.' Physiological Reviews, 93(1), 405-480. View published research
• Chow, B. S., et al. (2019). 'The relaxin receptor agonist B7-33 prevents and reverses tissue fibrosis.' Frontiers in Pharmacology, 10, 363. View published research
• Sarwar, M., et al. (2017). 'The monomeric relaxin-2 analogue B7-33 is a biased agonist.' British Journal of Pharmacology, 174(21), 3790-3801. View published research
• Kamat, F. M., et al. (2020). 'In vitro characterization of B7-33 in human airway smooth muscle cells.' American Journal of Respiratory Cell and Molecular Biology, 62(5), 580-591. View published research

⚠️ Research Use Only Disclaimer: All peptides and compounds are sold strictly for in-vitro laboratory research purposes only. Not intended for human or veterinary use, not a dietary supplement, and not approved to diagnose, treat, cure, or prevent any disease or condition. For use by qualified researchers in suitably equipped laboratory environments only. Amino Peptides Ltd operates in full compliance with UK MHRA regulations and applicable EU research chemical guidelines.